Carvedilol Phosphate Capsule, Extended Release
Product Images NDC 63629-9635

7 FDA label images from Bryant Ranch Prepack · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Carvedilol Phosphate (NDC 63629-9635). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (Carvedilol 1)

Structure (Carvedilol 1)
Chemical structure of Carvedilol Phosphate showing the detailed molecular arrangement including aromatic rings, hydroxyl, methoxy groups, and phosphate with associated water molecules.*
FDA Label Image

Figure-1 (Carvedilol Figure1)

Figure-1 (Carvedilol Figure1)
A line graph comparing cumulative mortality percentages over a 21-month period between two groups labeled 'Placebo' and 'Carvedilol'. The graph includes a statistical significance value (P = 0.0014) indicating differences between the groups.*
FDA Label Image

Figure-2 (Carvedilol Spl Figure 2)

Figure-2 (Carvedilol Spl Figure 2)
A forest plot displaying hazard ratios for different patient subgroups including men, women, age groups, racial groups, diabetic status, ischemic conditions, heart rate categories, blood pressure, and spironolactone use, with point estimates and confidence intervals plotted along a horizontal axis ranging from 0.0 to 2.0.*
FDA Label Image

Figure-3 (Carvedilol Figure3)

Figure-3 (Carvedilol Figure3)
A Kaplan-Meier survival curve chart comparing mortality percentages over months between Carvedilol phosphate extended-release treatment and placebo. The x-axis represents months from 0 to 24, and the y-axis represents percentage mortality from 0 to 30%. The Carvedilol group shows consistently lower mortality rates compared to placebo, with a reported p-value of 0.03 indicating statistical significance.*
FDA Label Image

Figure-4 (Carvedilol Spl Figure 4)

Figure-4 (Carvedilol Spl Figure 4)
This figure is a forest plot showing hazard ratios with confidence intervals for various patient subgroups related to myocardial infarction (MI) treatment outcomes. The subgroups include age, gender, randomization timing post-MI, prior beta-blocker use, Killip class, use of thrombolytics, PTCA status, presence of congestive heart failure, use of diuretics, angina, hypertension, diabetes, heart rate, and systolic blood pressure. Two hazard ratio scales range from 0.4 to 1.3, with a reference line at 1.0.*
FDA Label Image

Figure (Carvedilol 2)

Figure (Carvedilol 2)
This image contains two line graphs showing the change in systolic blood pressure (SBP) and diastolic blood pressure (DBP) over 24 hours after a morning dose of carvedilol phosphate extended-release capsules at 20 mg, 40 mg, and 80 mg doses. The graphs depict blood pressure changes tracked hourly and use locally weighted regression smoothing methodology.*
FDA Label Image

Label (Lbl636299635)

Label (Lbl636299635)
Label for Carvedilol Phosphate extended-release capsules, 80 mg strength. The label indicates a package size of 30 capsules, repackaged by Bryant Ranch Prepack, Inc., Burbank, CA, and manufactured by Frontida BioPharm Inc. It includes storage instructions and warnings, with NDC 63629-9635-1 and barcodes visible.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.